The availability of single administration therapies would have a major impact on the goal for malaria eradication by ensuring patient compliance and reducing treatment failures. However, this ambitious goal presents significant challenges in drug discovery where new molecules need to have the appropriate balance of properties to deliver a long half-life and extended duration of exposure. In this presentation, these challenges will be discussed along with tools being applied in drug discovery to obtain an early indication of the likely human PK profile.